Despite UBS expecting the shares of Filtrona to trade sideways until a strategic review on 25 August, the broker raises its target price by 55p, saying that it is "[o]nly the beginning of the new day.""From here, we believe the investment case will be more focused on the actual delivery rather than the concept of what management can do," said analyst Alex Hugh.At the review, the broker expects the speciality plastic and fibre products supplier to put out targets for higher revenue growth, acquisitions and improved capital efficiencies. "On our base case forecasts, the stock looks fully valued. With the re-rating story having played out, we believe further upside to the shares will be driven by consensus earnings upgrades from higher organic growth, self help measures and acquisition growth," Hugh said.The target price now stands at 430p, up from 375p previously. A 'buy' rating is maintained.---BC